Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Double-Blind Study of HDP 99.0006 in Actinic Keratosis
2005-000394-21Phase 2Completed
- Sponsor
- Heidelberg Pharma AG
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fosfluridine tidoxil in actinic keratosis (AK) (3 arms), sponsored by Heidelberg Pharma AG. Primary endpoint: Percent change in number of AK lesions at visit 15 vs baseline. Started Dec 2005; status: completed.
02
Drugs
fosfluridine tidoxil
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2005-000394-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000394-21.